LDS/Medical Tests/Decipher Bladder Cancer Genomic Profiling

Decipher Bladder Cancer Genomic Profiling

Bladder cancer is the fourth most common cancer in males and the risk of developing bladder cancer is 4-5 fold greater in males than in females. Initially, benign tumor(s) arise within the bladder lining or deep tissue which later undergo malignant transformation and may metastasize. Clinical findings include hematuria, lower back pain along with frequent and painful urination. The major cause of bladder cancers is germline mutations in FGFR3, PIK3CA, KDM6A, or TP53. Decipher bladder cancer genomic profiling allows comprehensive and accurate diagnosis of bladder cancers along with subtype specification.

Various studies have shown that utilization of the Decipher assay generated more accurate and easy results as compared to individual genetic testing. It is a molecular profiling test that uses gene expression analysis from bladder cancer specimens obtained by transurethral resection. The cancer is classified into 4 subtypes: luminal, luminal-infiltrated, basal, and neuroendocrine-like. Each of these subtypes is found to have a distinct biological pattern. Decipher assay is highly indicated for patients considering neoadjuvant chemotherapy (NAC). The assay is capable to predict the survival benefit from NAC in bladder cancer patients. The company claims that the Decipher assay aids clinicians in the decision whether to immediately proceed the patient to cystectomy or follow NAC for the better survival of the patient.

Although, numerous tests and test panels for diagnosing bladder have been developed that utilize DNA (Urovysion FISH), RNA (Cxbladder test, Xpert Bladder Cancer Monitor), protein antigens (Complement factor H), and/or nuclear matrix proteins (NMP22, BLCA-4, BLCA-1), none of these are currently recommended by the NCCN or major societies for screening or diagnosis of bladder cancer as a replacement for cystoscopy and biopsy.

As an aid in the diagnosis, subtyping and prognosis of bladder cancer
Molecular sub-type (luminal, luminal infiltrated, basal, neuroendocrine-like) reported.

Normal, no cancer found

Gene expression analysis, microarray gene expression profiling.

Trans-urethral resection of bladder tumor (TURBT).

Formalin-fixed, paraffin-embedded tissue.

Stability

  • Formalin-fixed, paraffin-embedded tissue are stable at room temperature for longer. 
Bladder biopsy, Fluorescent in-situ hybridization (FISH), bladder tumor-associated antigen (BTA), urinalysis, renal function tests, CBC, urine culture, carcinoembryonic antigen (CEA), FGFR3, PIK3CA, KDM6A, TP53 gene mutation analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login